[13C6]-Tafamidis

[13C6]-Tafamidis is a molecule used in pharmacological research to study the binding interactions between tafamidis and its target proteins. Tafamidis is a drug used to treat a rare genetic disease called transthyretin amyloidosis, which is caused by the accumulation of misfolded proteins in tissues and organs. Tafamidis works by stabilizing the structure of transthyretin, a protein that transports thyroid hormones and retinol-binding protein in the blood. By stabilizing transthyretin, tafamidis prevents the formation of amyloid fibrils that can damage organs such as the heart, nerves, and kidneys. [13C6]-Tafamidis is a labeled form of tafamidis that contains six carbon atoms with a mass of 13 atomic units instead of the usual 12. This labeling allows researchers to trace the fate of tafamidis in biological systems using mass spectrometry. Mass spectrometry is a technique that separates and measures the mass-to-charge ratio of ions in a sample, which can provide information on the chemical composition and structure of molecules. [13C6]-Tafamidis can be synthesized using organic chemistry methods that involve isotopic labeling of precursor molecules. Isotopic labeling involves replacing one or more atoms in a molecule with a heavier or lighter isotope of the same element, which can alter the physical and chemical properties of the molecule. The use of isotopic labeling in drug development and metabolism studies is a powerful tool for understanding the mechanisms of action and side effects of drugs in the body.